Skip to main content
Clinical Trials/CTIS2024-513430-37-00
CTIS2024-513430-37-00
Recruiting
Phase 1

The FACE (Facial nerve palsy And Cortisone Evaluation) study in children: a randomised double-blind, placebo-controlled, multicenter trial. - FACE-01

Region Dalarna0 sitesMay 16, 2024

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Facial Nerve Palsy (Bells Palsy)
Sponsor
Region Dalarna
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 16, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Region Dalarna

Eligibility Criteria

Inclusion Criteria

  • 1\-17 years of age, Acute peripheral facial nerve palsy, Less than 72 hours of duration of symptoms, Signed informed consent.

Exclusion Criteria

  • Trauma, Use of any systemic or inhaled steroids within 2 weeks prior onset of symptoms, Immunization with live vaccine 1 month prior onset of symptoms, Requirement of live vaccine within 2 months from start of experimental treatment (prednisolone or placebo), Evaluation of primary endpoint at 12 months not feasible for any reason, Previously included into the FACE study, Central facial nerve palsy, Malformations in head and neck, Conditions not compatible with cortisone treatment (hypertension, diabetes mellitus type 1, psychiatric disorder, active or latent tuberculosis, intolerance of lactose), Current or past oncological diagnosis, Other serious medical conditions (meningitis, encephalitis, stroke), Acute otitis media, Signs of herpes simplex or varicella zoster infection (vesicles in the ear region), Pregnancy or breastfeeding

Outcomes

Primary Outcomes

Not specified

Similar Trials